taking tirzepatide and retatrutide together Switching from to retatrutide: the complete transition guide Retatrutide vs Tirzepatide: Triple vs

Two GLP-1 receptor agonist drugs (liraglutide and semaglutide) have FDA approval for treatment of overweight/obesity independent of diabetes mellitus

Ethics approval The study followed the principles in the Declaration of Helsinki and was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (IRB Ref.: UW 15-126)

It is the first of these medications to interact with two hormones in the body, which is why researchers believe it manages blood sugar levels better than previous medicines and helps people lose more weight

While semaglutide activates one receptor (GLP-1) and tirzepatide activates two (GLP-1 and GIP), retatrutide activates three: GLP-1, GIP, and glucagon receptors simultaneously

Discontinuation rate: 10.6% at the 12mg dose due to adverse events